HealthMore in Health→
Coultreon Launches With $125 Million to Chase Autoimmune Drugs Built Around SIK Inhibition
Key Takeaways
- Coultreon Biopharma raised $125 million from major biotech investors.
- The company is a Galapagos spinout targeting autoimmune disease.
- Its strategy is centered on a differentiated SIK inhibition approach.
DE
DT Editorial Team··via endpoints.news